Top 100 US Wachstums Aktien
Die Übersicht zeigt die 100 US Aktien mit dem besten Umsatzwachstum im letzten abgelaufenen Quartal.
Das Wachstum bezieht sich auf das Quartal zum Vorjahr und zeigt die prozentuale Steigerung des Umsatz.
Die Aktien sind sortiert nach Umsatzwachstum startend mit dem höchsten Wachstum auf Platz 1. Die Marktkapitalisierung aller Aktien beträgt mindestens 100 Mio USD.
| Aktie | ISIN | Wachstum Quartal | |||
|---|---|---|---|---|---|
| #1 | Keros Therapeutics Inc | US4923271013 | 49.002,70 % | ||
| #2 | Regulus Ther.compar | US75915K3095 | 27.677,80 % | ||
| #3 | Cytokinetics | US23282W6057 | 26.714,90 % | ||
| #4 | Faraday Future Intelligent Electric | US3073598852 | 15.700,00 % | ||
| #5 | QXO, | US82846H4056 | 13.047,60 % | ||
| #6 | Verb Technology Company | US92337U1043 | 5.637,80 % | ||
| #7 | Geron | US3741631036 | 5.459,60 % | ||
| #8 | Sangamo Therapeutics | US8006771062 | 5.042,10 % | ||
| #9 | BridgeBio Pharma | US10806X1028 | 4.999,89 % | ||
| #10 | CorMedix | US21900C3088 | 4.829,39 % | ||
| #11 | Mict | US55328R1095 | 4.161,30 % | ||
| #12 | Ovid Therapeutics | US6904691010 | 3.611,20 % | ||
| #13 | Silverback Therapeutics Inc | US82835W1080 | 3.043,40 % | ||
| #14 | Reata | US75615P1030 | 2.885,00 % | ||
| #15 | ImmunityBio | US45256X1037 | 2.423,90 % | ||
| #16 | reAlpha Tech Common Stock | US75607T1051 | 1.908,50 % | ||
| #17 | Brandywine Realty | US1053682035 | 1.668,30 % | ||
| #18 | Lexicon | US5288723027 | 1.652,60 % | ||
| #19 | Eos Energy Enterprises | US29415C1018 | 1.596,70 % | ||
| #20 | Eos Energy Enterprises | US29415C1190 | 1.596,70 % | ||
| #21 | Provention Bio | US74374N1028 | 1.408,10 % | ||
| #22 | Madrigal | US5588681057 | 1.353,80 % | ||
| #23 | Praxis Precision Medicines Inc | US74006W2070 | 1.349,10 % | ||
| #24 | Chimerix | US16934W1062 | 1.325,00 % | ||
| #25 | Immersion | US4525211078 | 1.323,80 % | ||
| #26 | Meiragtx | KYG596651029 | 1.208,90 % | ||
| #27 | Inhibrx Biosciences, | US45720N1037 | 1.200,00 % | ||
| #28 | Ault Global Holdings | US05150X1046 | 1.050,30 % | ||
| #29 | Syndax | US87164F1057 | 984,50 % | ||
| #30 | CTI BioPharma | US12648L6011 | 950,80 % | ||
| #31 | Genius Brands | US37229T3014 | 884,70 % | ||
| #32 | Nuscale Power | US67079K1007 | 732,90 % | ||
| #33 | Gevo | US3743964062 | 725,30 % | ||
| #34 | NeoVolta Common Stock | US6406551068 | 720,20 % | ||
| #35 | American Battery Technology Company Common St... | US02451V3096 | 708,10 % | ||
| #36 | Cadiz | US1275372076 | 704,30 % | ||
| #37 | Poseida Therapeutics | US73730P1084 | 667,20 % | ||
| #38 | ImmunoGen | US45253H1014 | 637,70 % | ||
| #39 | Editas Medicine | US28106W1036 | 597,50 % | ||
| #40 | Great Ajax | US38983D3008 | 592,20 % | ||
| #41 | Annaly Capital Management | US0357108390 | 576,60 % | ||
| #42 | Ondas Holdings | US68236H2040 | 554,90 % | ||
| #43 | PureTech Health | US7462371060 | 542,70 % | ||
| #44 | Arbutus Biopharma | CA03879J1003 | 522,20 % | ||
| #45 | KemPharm | US4884452065 | 481,70 % | ||
| #46 | Verve Therapeutics | US92539P1012 | 479,00 % | ||
| #47 | Tscan Therapeutics | US89854M1018 | 473,90 % | ||
| #48 | Chesapeake Energy | US1651677353 | 446,50 % | ||
| #49 | Beta Bionics, Common Stock | US08659B1026 | 440,10 % | ||
| #50 | Phathom Pharmaceuticals | US71722W1071 | 439,40 % | ||
| #51 | Belpointe Prep Llc Unit | US0806941029 | 421,40 % | ||
| #52 | Invitation Homes | US46187W1071 | 420,60 % | ||
| #53 | CoreWeave | US21873S1087 | 420,30 % | ||
| #54 | Monte Rosa Therapeutics | US61225M1027 | 394,00 % | ||
| #55 | BTCS | US05581M4042 | 394,00 % | ||
| #56 | Aeluma, Common Stock | US00776X1090 | 370,80 % | ||
| #57 | Amprius Technologies | US03214Q1085 | 350,40 % | ||
| #58 | Silver Spike Investment | US8281741020 | 324,50 % | ||
| #59 | Day One Biopharmaceuticals | US23954D1090 | 313,89 % | ||
| #60 | Progenity | US74319F1075 | 310,39 % | ||
| #61 | Arcus Biosciences | US03969F1093 | 310,30 % | ||
| #62 | Dynex Capital | US26817Q8868 | 309,00 % | ||
| #63 | Atea Pharmaceuticals Inc | US04683R1068 | 295,20 % | ||
| #64 | Earthstone Energy | US27032D3044 | 292,70 % | ||
| #65 | Duos Technologies | US2660424076 | 279,70 % | ||
| #66 | NLY-P-I | US0357108705 | 275,30 % | ||
| #67 | Annaly Capital Management | US0357108622 | 275,30 % | ||
| #68 | Siga | US8269171067 | 271,89 % | ||
| #69 | Sage Therapeutics | US78667J1088 | 265,80 % | ||
| #70 | TSS Inc | US87288V1017 | 261,60 % | ||
| #71 | KKR Real Estate Finance | US48251K1007 | 245,10 % | ||
| #72 | Profrac Holding | US74319N1000 | 237,40 % | ||
| #73 | Nuvation Bio | US67080N1019 | 236,80 % | ||
| #74 | American Res | US02927U2087 | 223,70 % | ||
| #75 | SoundHound AI | US8361001071 | 217,10 % | ||
| #76 | Nutex Health | US67079U1088 | 214,00 % | ||
| #77 | Zogenix | US98978L2043 | 213,00 % | ||
| #78 | Delcath Systems | US24661P8077 | 211,00 % | ||
| #79 | Blade Air Mobility | US0926671043 | 208,30 % | ||
| #80 | KEY-P-L | US4932677028 | 202,60 % | ||
| #81 | KeyCorp | US4932671088 | 202,60 % | ||
| #82 | KeyCorp | US4932678687 | 202,60 % | ||
| #83 | KeyCorp | US4932678760 | 202,60 % | ||
| #84 | Mirati Therapeutics | US60468T1051 | 202,00 % | ||
| #85 | Flowco Holdings | US3429091081 | 200,80 % | ||
| #86 | 4D Molecular Therapeutics Inc | US35104E1001 | 200,00 % | ||
| #87 | Janone | US47089W1045 | 194,10 % | ||
| #88 | VistaGen Therapeutics | US92840H2022 | 190,50 % | ||
| #89 | Stoke Therapeutics | US86150R1077 | 186,00 % | ||
| #90 | Rigel Pharmaceuticals | US7665597024 | 176,00 % | ||
| #91 | Aeva Technologies | US00835Q1031 | 173,90 % | ||
| #92 | Sunrise Realty Trust, | US8679811021 | 172,60 % | ||
| #93 | Franklin BSP Realty Trust | US35243J1016 | 171,50 % | ||
| #94 | Albireo Pharma | US01345P1066 | 168,30 % | ||
| #95 | Arcutis Biotherapeutics Inc | US03969K1088 | 164,10 % |
Vor ziemlich genau einem Jahr meldete Intel das bisher schlechteste Quartalsergebnis der Unternehmensgeschichte. Satte 16,6 Milliarden US-Dollar an Verlust musste...
WeiterlesenDie Börsen haben in Beyond Meat ihre neue Meme-Aktie gefunden und in der ausgelaufenen Woche überschlugen die Ereignisse sich regelrecht....
WeiterlesenSiemens scheint sich derzeit im Umbruch zu finden und CEO Roland Busch stimmte bei der internen Siemens Business Conference schon...
Weiterlesen